ArcticZymes Technologies ASA logo

ArcticZymes Technologies ASA (AZT)

Market Closed
8 Dec, 14:20
XOSL XOSL
kr
19. 00
-0.9
-4.52%
kr
689.46M Market Cap
120.29 P/E Ratio
0% Div Yield
54,739 Volume
0.44 Eps
kr 19.9
Previous Close
Day Range
19 20
Year Range
13 31.4
Want to track AZT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 65 days

Summary

AZT closed today lower at kr19, a decrease of 4.52% from yesterday's close, completing a monthly decrease of -27.76% or kr7.3. Over the past 12 months, AZT stock gained 35.71%.
AZT is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Feb 11, 2026.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

AZT Chart

ArcticZymes Technologies ASA (AZT) FAQ

What is the stock price today?

The current price is kr19.00.

On which exchange is it traded?

ArcticZymes Technologies ASA is listed on XFRA.

What is its stock symbol?

The ticker symbol is AZT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 689.46M.

When is the next earnings date?

The next earnings report will release on Feb 11, 2026.

Has ArcticZymes Technologies ASA ever had a stock split?

No, there has never been a stock split.

ArcticZymes Technologies ASA Profile

Biotechnology Industry
Healthcare Sector
Dr. Marie Ann Roskrow BSc. (Hons), MBBS (Hons), Ph.D. CEO
XOSL Exchange
NO0010014632 ISIN
Norway Country
53 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

ArcticZymes Technologies ASA is a prominent life sciences company rooted in Tromsø, Norway, with operations spanning globally, including significant presences in Norway, Germany, Lithuania, Italy, the United States, and other parts of Europe. Initially founded in 1990 and known as Biotec Pharmacon ASA, the company underwent a rebranding to ArcticZymes Technologies ASA in June 2020. ArcticZymes specializes in developing, manufacturing, and commercializing recombinant enzymes for a wide range of applications including molecular research, in vitro diagnostics, and biomanufacturing. The company's innovative approach to enzyme technology underscores its commitment to facilitating advancements in the life sciences sector.

Products and Services

ArcticZymes Technologies ASA offers a diverse portfolio of specialized enzymes and related products designed to meet the rigorous demands of molecular research, diagnostics, and biomanufacturing. These products include:

  • Salt Active Nuclease: This enzyme is tailored for the removal of nucleic acids during the manufacturing of viral vectors, recombinant proteins, and other biological reagents, enhancing purity and yield in bioprocessing workflows.
  • Shrimp Alkaline Phosphatase: Optimized for the clean-up processes preceding Sanger sequencing and next-generation sequencing applications, ensuring high-quality results in genetic analysis.
  • Cod UNG (Uracil-DNA Glycosylase): Specifically designed for use in viral and other molecular diagnostic assays, this enzyme is instrumental in reducing the risk of carry-over contamination in PCR and qPCR workflows.
  • Double-Strand Specific DNases and Derived Kits: These products target the removal of double-stranded DNA, playing a crucial role in preventing contamination and improving the accuracy of molecular assays.
  • Polymerases: The company offers a range of polymerases suited for technology development applications across life science research, molecular diagnostics, next-generation sequencing (NGS), and synthetic biology, highlighting their versatility and high performance.
  • Proteinase: Designed for applications in microbiological diagnostics and liquid biopsies, this enzyme aids in the efficient breakdown of protein samples, facilitating easier analysis and detection of microbial and other biological entities.
  • Ligases: These enzymes are crucial for joining nucleic acids, enabling their use in various genetic engineering, sequencing, and molecular cloning applications, thereby supporting advanced research and development in genetics and biotechnology.

Contact Information

Address: SIVA Innovation Centre
Phone: 47 77 64 89 00